About Us
TheWell Bioscience is pioneering xeno-free 3D biomimicking platforms to drive the future of advanced biomedicine. We are shaping a world where human-relevant 3D systems are the foundation of how new therapies are discovered, validated, and ultimately delivered to patients. Our mission is to unlock the full potential of 3D cell technology for clinical translation and laboratory automation—bringing biological precision and operational efficiency together into one seamless ecosystem.
To achieve this, we are building a comprehensive end-to-end, xeno-free workflow that empowers robust and reproducible 3D models across every stage of research and development. Our platform serves as the bridge from early discovery to clinical deployment. By eliminating reliance on animal-derived materials and improving the fidelity of in vitro models, we accelerate drug discovery, reduce experimental variability, and expand the possibilities of personalized medicine.
A major focus of our innovation is advancing cell and tissue preservation and organoid development technologies that support regenerative medicine. We enable long-term cell viability, improved post-thaw function, and efficient organoid recovery—capabilities crucial for clinical success. Leveraging the versatility of our 3D hydrogel platform, we also provide injectable biomaterials that can deliver therapeutic cells and biologics directly to target tissues, supporting localized repair and controlled therapeutic release.
In addition, we are developing the next generation of scalable, xeno-free 3D culture systems tailored for advanced biomanufacturing. These technologies are designed to enable consistent, GMP-ready production of organoids and tissues that meet stringent regulatory and quality standards. By supporting automation, batch control, and large-scale workflows, our solutions pave the way for clinical-grade tissue models and future patient-specific therapeutics.
Our technology ecosystem is built around a portfolio of innovative product families that work synergistically to advance 3D biology:
- VitroGel® — versatile xeno-free hydrogels supporting organoid, spheroid, and tissue engineering
- VitroINK® — precision bioinks engineered for reliable bioprinting and structured tissue assembly
- RocketCell™ — robust media and reagents that streamline cell expansion and 3D-ready workflows
- VitroPrime™ — advanced surface-engineered plates for optimized 2D-to-3D hybrid culturing
- CytoGrow™ — defined supplements and growth factors for controlled expansion and differentiation
- Cyto3D™ — innovative tools enabling standardized 3D cell analysis and quantifiable biological insights
Together, these product families power an all-in-one, xeno-free platform that transforms how scientists model disease, engineer functional tissues, and translate 3D cell technologies into real-world clinical and commercial impact.
At TheWell Bioscience, we are committed to enabling the next era of precision medicine—where safer, more effective therapies are guided by human-relevant models and delivered through scalable, clinically aligned technology. We are not just advancing 3D cell culture; we are redefining what is possible for the future of human health.
